Unsplash+Finnish clinical stage biotech TenBoron Oy has landed a €7.6m grant from the European Union’s Horizon Europe Health 2025 programme. The funding will propel its boron carrier platform for a novel targeted radiotherapy into larger clinical trials for cancers with few remaining treatment options.
ADVERTISEMENT